Top

Novartis’ $4 Million Gene Therapy — Real Price Or A Negotiation Ploy?

November 13, 2018

Via: Forbes
Category:

At its annual R&D investor day, Novartis updated the world on its drug pipeline and research priorities. It was an impressive session befitting a company that spends $9 billion annually on R&D (about 18% of its top line revenues). Novartis touted a pipeline that includes more than 200 programs in clinical development encompassing over 500 ongoing clinical trials with 26 potential blockbusters in late stage development. Its pipeline is truly enviable and teems with potential new treatments in a variety of therapeutic areas including various types of cancer, heart disease, metabolic disorders and rare diseases.

Read More on Forbes